The FDA has approved peanut allergen powder-dnfp (Palforzia – Aimmune) for use as oral immunotherapy to mitigate allergic reactions, including anaphylaxis, caused by accidental peanut exposure in patients with a confirmed peanut allergy (Box). It is the first drug to be approved in the US for this indication; Viaskin Peanut, an immunotherapy patch, is under FDA review for the same indication.
Peanut Allergen Powder (Palforzia). JAMA. 2020;324(2):192–193. doi:10.1001/jama.2020.3599
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: